The impact of inspiratory effort on inspiratory flow through Turbuhaler® in asthmatic patients

European Respiratory Journal

Volumn 10, Issue 3, 1997, Pages 681-684

  Persson, G ^a   Olsson, B ^b   Soliman, S ^c,d  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Astra Draco AB   (Sweden)

^c Clinical Research and Development   (Sweden)

^d Research and Development Department   (Sweden)

Author keywords

inhalation technique; peak inspiratory flow; Turbuhaler

Indexed keywords

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALER; INSPIRATORY CAPACITY; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADULT; ASTHMA; FEMALE; HUMANS; INHALATION; MALE; NEBULIZERS AND VAPORIZERS; SINGLE-BLIND METHOD;

EID: 0031054488     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Crompton GK. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis 1982; 63: 101-104.
2. Jackson L, Ståhl E, Holgate ST. Terbutaline via pressurized metered-dose inhaler (pMDI) and Turbuhaler® in highly reactive asthmatic patients. Eur Respir J 1994; 7: 1598-1601.
3. Ganderton D, Kassem NM. Dry powder inhalers. Adv Pharm Sci 1992; 6: 165-191.
4. Pedersen S, Frost L, Anfred T. Error in inhalation technique and efficacy in inhaler use in asthmatic children. Allergy 1986; 41: 118-124.
5. Nimmo CJR, Chen DNM, Martinusen SM, Ustad TL, Ostrow DN. Assessments of patients acceptance and inhalation technique of a pressurised aerosol inhaler and two breath-actuated devices. Ann Pharmacother 1993; 27: 922-927.
6. Jaegfeldt H, Andersson JAR, Trofast E, Wetterlin K. Particle size distribution from different modifications of Turbuhaler®. In: Newman SP, Morèn F, Crompton GK, eds. A New Concept in Inhalation Therapy. London, Medicom, 1987; pp. 90-99.
7. Olsson B, Asking L. Critical aspects of the function of inspiratory flow driven inhalers. J Aerosol Med 1994; 7 (Suppl. 1): S43-S47.
8. Borgström L, Bondesson E, Morèn F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994; 7: 69-73.
9. Newman SP, Morèn F, Trofast E, Talaee N, Clarke SW. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int J Pharm 1991; 74: 209-213.
10. Richards R, Dickson CR, Renwick AG, Lewis RA, Holgate ST. Absorption and disposition kinetics of cromolyn sodium and the influence of inhalation technique. J Pharmacol Exp Ther 1987; 241: 1028-1031.
11. Newman SP, Demetri P, Clarke SW. Improving the bronchial deposition of pressurized aerosol. Chest 1981; 80 (Suppl. 6): 909-911.
12. Newman S, Steed K, Hooper G, Källen A, Borgström L. Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered-dose inhaler. Pharmacol Res 1995; 12(2): 231-236.
13. Wetterlin K. Turbuhaler: a new powder inhaler for administration of drugs to airways. Pharmacol Res 1988; 5(8): 506-508.
14. Jordanglou J, Pride NB. A comparison of maximum inspiratory and expiratory flow in health and in lung disease. Thorax 1968; 23: 38-45.
15. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers: implications for in vitro testing. J Aerosol Med 1993; 6(2): 99-110.
16. Engel T, Heinig JH, Madsen F, Nikander K. Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler®). Eur Respir J 1990; 3: 1037-1041.
17. Brown PH, Greening AP, Crompton GK. Peak inspiratory flow rates in acute asthma: are they adequate for efficient use of a Turbuhaler. Thorax 1992; 47: 239P.
18. Thorsson L, Edsbäcker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler® is twice that from a pressurized metered-dose inhaler, P-MDI. Eur Respir J 1994; 7: 1839-1844.
19. Agertoft L, Pedersen S. Importance of inhalation device on the effect of budesonide. Arch Dis Child 1993; 69: 130-133.
20. Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R. Inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996; 153: 1636-1640.
21. Löfdahl CG, Andersson S, Bondesson E, et al. Salbutamol doses inhaled via Turbuhaler® give a better bronchodilating effect than when given via a pressurized metered dose inhaler. Eur Respir J 1994; 7: 49s.
22. Matusiewicz SP, Böllert FGE, Dewar M, et al. Ipratropium bromide given by Turbuhaler® is more potent than when given by pressurized-metered dose inhaler (MDI). Thorax 1995; 50(4): 469P.
23. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990; 65: 308-310.
24. Engel T, Scharling B, Skovsted B, Heinig JH. Effects, side-effects and plasma concentrations of terbutaline in adult asthmatics after inhaling from a dry powder inhaler device at different inhalation flows and volumes. Br J Clin Pharmacol 1992; 33: 439-444.